Floatz logo

Inotuzumab Ozogamicin

Acute Lymphoblastic Leukaemia

Ruijin Hospitalantibody_drug_conjugatePhase 1Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

73 Active assets in the Acute Lymphoblastic Leukaemia cohort.

Asset / SponsorPhaseRating
MERCAPTOPURINE ANHYDROUS
Shanxi Bethune Hospital
Phase 4A
Cytosin-Arabinosid
PETHEMA Foundation
Phase 4BBB
Cyclophosphamide
The First Affiliated Hospital of Zhengzhou University
Phase 4BBB
METHOTREXATE
PETHEMA Foundation
Phase 4BBB
DEXAMETHASONE
Shanxi Bethune Hospital
Phase 4BBB

View all 50 →

Same molecule, other indications

Inotuzumab Ozogamicin is also rated in:

acute lymphoblastic leukemiaDormant
BB
Indicative ·
69 / 100
View asset →
B-cell acute lymphoblastic leukemiaDormant
BB
Indicative ·
68 / 100
View asset →
B Lymphoblastic LymphomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →